Sermorelin vs tesamorelin
Sermorelin vs tesamorelin: which is better, and for what?
Sermorelin vs tesamorelin comes down to the condition being treated and the exact product. Both stimulate the growth-hormone pathway, but tesamorelin has an FDA-approved product for excess abdominal fat in adults with HIV and lipodystrophy. That is not approval for general weight loss. The current compounded sermorelin plans compared here are not FDA-approved. For general fat loss, muscle gain or anti-aging, the studies below do not establish a head-to-head winner. The useful distinction is between a result measured in a defined patient group and a benefit advertised to everyone.
Selected human evidence and US product information, not a systematic review or a treatment recommendation. We compare online sermorelin plan terms separately from clinical effectiveness.
| Question | Sermorelin | Tesamorelin |
|---|---|---|
| How do they work? | A GHRH(1-29) analogue that stimulates growth-hormone release. | A GHRH analogue that also stimulates the growth-hormone pathway. |
| Which product is approved? | Historical Geref products were discontinued. Current compounded plans are not FDA-approved. | EGRIFTA WR has an FDA-labeled HIV-lipodystrophy indication. An unapproved vial does not inherit it. |
| Is this general weight-loss treatment? | The selected human evidence does not establish it. | No. The EGRIFTA WR label says it is not indicated for weight-loss management. |
| What human result matters? | A small six-week study found no change in measured muscle or fat mass. | A 404-person HIV trial reduced visceral abdominal fat versus placebo at six months. |
| Can the products be substituted? | No dose or outcome equivalence established here. | Even EGRIFTA WR and EGRIFTA SV are not substitutable formulations. |
What do human studies of sermorelin and tesamorelin show?
Swipe the study table sideways to read all four columns.
| Study | People and duration | Finding | Limit |
|---|---|---|---|
| Vittone et al., 1997: injected GHRH(1-29) | 11 healthy men aged 64 to 76 with low baseline IGF-I; six weeks | Nighttime GH increased; two of six strength measures improved. No change in measured muscle or fat mass. | Small before-and-after study; no tesamorelin comparison or proof of a modern compounded plan's results. |
| Falutz et al., 2010: tesamorelin versus placebo | 404 adults with HIV and excess abdominal fat; six-month randomized phase, then six-month extension | Visceral fat fell 10.9% with tesamorelin versus 0.6% with placebo at six months. | Applies to that clinical population and abdominal visceral fat, not general weight loss or a bodybuilding comparison. |
What is the difference between sermorelin and tesamorelin?
Both are growth hormone-releasing hormone analogues, but a shared pathway does not make their products, indications or results interchangeable. Tesamorelin's current EGRIFTA WR label describes a particular prescription product and patient group. Sermorelin's historical Geref record is separate from today's compounded offers.
Identify the actual prescription first. A research-use vial or a compounded product is not the FDA-approved finished drug simply because the ingredient name matches.
How do sermorelin, tesamorelin and ipamorelin compare?
They fall into two groups. Sermorelin and tesamorelin are both growth hormone-releasing hormone analogues. Ipamorelin acts on the ghrelin receptor, a different route to growth hormone release. Of the three, only tesamorelin has a current FDA-approved product, and its indication is excess abdominal fat in adults with HIV and lipodystrophy.
The evidence does not rank them. Tesamorelin has a randomized trial of 404 adults with HIV and excess abdominal fat. Sermorelin's six-week study in eleven older men found no change in measured muscle or fat mass. Ipamorelin's randomized trial gave an intravenous product to 117 patients after bowel surgery and found no significant difference from placebo on its efficacy measures. No trial compares the three head to head.
FDA's compounding risk page lists ipamorelin acetate in 503B Category 2 and cites possible immune reactions and impurities. Taking the three together is a separate treatment claim that none of these studies tested. Do not combine or substitute them on the strength of a comparison page.
Swipe the table sideways to read all 4 columns.
| Question | Sermorelin | Tesamorelin | Ipamorelin |
|---|---|---|---|
| Receptor | GHRH receptor | GHRH receptor | Ghrelin receptor |
| FDA-approved product today | None. Geref is discontinued and its approvals were withdrawn | EGRIFTA WR, for excess abdominal fat in adults with HIV and lipodystrophy | None identified in the FDA materials reviewed |
| Human study cited here | Six weeks in eleven older men: no change in measured muscle or fat mass | Six months in 404 adults with HIV: visceral fat fell 10.9%, against 0.6% on placebo | Up to seven days of intravenous dosing in 117 bowel-surgery patients: no significant benefit over placebo |
| FDA compounding record | Compounded sermorelin is not FDA-approved | A compounded version is not the approved drug | Listed in 503B Category 2 for significant safety concerns |
- FDA: EGRIFTA WR prescribing information (March 2025)
- Falutz et al.: randomized tesamorelin trial in HIV-associated abdominal fat (2010)
- FDA: discontinued Geref sermorelin determination (2013)
- FDA: understanding the risks of compounded drugs
- Vittone et al.: six-week GHRH(1-29) study in older men (1997)
- FDA: bulk substances that may present significant compounding risks
- Beck et al.: randomized IV ipamorelin postoperative trial (2014)
Is tesamorelin better than sermorelin for fat loss?
Tesamorelin has randomized evidence for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy. In the 404-person trial above, the six-month reduction was greater than placebo. That supports a defined use; it does not establish superiority over sermorelin for weight loss in the general population.
Visceral fat surrounds internal organs. A change in that compartment is not the same as losing an equivalent percentage of body weight. EGRIFTA WR is not indicated for weight-loss management, and the trial did not compare tesamorelin with sermorelin.
Which is better for muscle growth or anti-aging?
Neither is established as the better option by the selected studies. The small GHRH(1-29) study found some strength changes without increased measured muscle mass. A growth-hormone response and a strength test are different outcomes from muscle growth.
Tesamorelin's abdominal-fat evidence does not settle a bodybuilding or lifespan question. A relevant comparison would need the same population, actual products and a prespecified outcome. Before-and-after photographs and different studies placed side by side do not provide that.
Are EGRIFTA WR and EGRIFTA SV the same?
They contain tesamorelin but are not substitutable formulations. The March 2025 FDA label for EGRIFTA WR states that WR and SV differ in dosage, preparation and storage. Follow the instructions for the exact prescribed product rather than reusing another version's instructions.
EGRIFTA WR's indication is excess abdominal fat in adults with HIV and lipodystrophy. Historical Geref approval does not make compounded sermorelin an approved alternative.
What are the safety differences?
EGRIFTA WR has defined warnings, including elevated IGF-I, fluid retention and glucose intolerance or diabetes. Its label lists pregnancy, active malignancy and disruption of the hypothalamic-pituitary axis among contraindications. A clinician must assess suitability and monitoring.
Compounded sermorelin is not reviewed by FDA before marketing for safety, effectiveness and quality. A shorter list of published risks is not evidence that it is safer. This comparison does not establish a comparative side-effect rate.
How should I compare cost and treatment plans?
Obtain the exact product name, prescription quantity, complete initial bill, renewal, pharmacy and required monitoring costs. A monthly sermorelin subscription cannot be treated as a clinically equivalent substitute for a tesamorelin prescription.
Our cost guide covers documented online sermorelin offers. We have not audited a comparable tesamorelin provider market, so we do not name a cheaper treatment or infer insurance coverage.
Which sources support this comparison?
These sources were checked October 11, 2026. They define the product, population and regulatory boundaries used above; they do not determine individual suitability.
- FDA: EGRIFTA WR prescribing information (March 2025)
- Falutz et al.: randomized tesamorelin trial in HIV-associated abdominal fat (2010)
- FDA: discontinued Geref sermorelin determination (2013)
- FDA: understanding the risks of compounded drugs
- Vittone et al.: six-week GHRH(1-29) study in older men (1997)
- FDA: bulk substances that may present significant compounding risks
- Beck et al.: randomized IV ipamorelin postoperative trial (2014)
Popular X vs Y questions
Continue with another evidence comparison.
We publish a comparison when people are searching for the distinction, even when only one side has audited providers. Inclusion is not an endorsement.
Sermorelin vs HGH
Compare current compounded sermorelin offers with prescription somatropin by product, FDA status, adult growth hormone deficiency evidence and what a plan price includes.
Sermorelin vs ipamorelin
Sermorelin and ipamorelin use different receptors. Compare human studies, fat-loss and muscle claims, FDA concerns and the limits of combination claims.
Sermorelin vs CJC-1295
Compare sermorelin and CJC-1295 by product identity, duration claims, FDA status and evidence limits. Understand why CJC-1295 forms cannot be grouped together.
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.